Daratumumab Injection ( DrugBank: Daratumumab )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 28 | Systemic amyloidosis | 1 |
| 49 | Systemic lupus erythematosus | 1 |
| 63 | Idiopathic thrombocytopenic purpura | 1 |
28. Systemic amyloidosis
Clinical trials : 267 / Drugs : 241 - (DrugBank : 77) / Drug target genes : 68 - Drug target pathways : 180
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05451771 (ClinicalTrials.gov) | October 26, 2022 | 6/7/2022 | Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis | An Open-label Phase I/II Trial of Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Systemic Light-Chain Amyloidosis | AL Amyloidosis | Drug: Venetoclax Oral Tablet, 200 mg;Device: FISH assay;Drug: Venetoclax Oral Tablet, 400 mg;Drug: Dexamethasone Oral, 10 mg;Drug: Dexamethasone Oral, 20 mg;Drug: Daratumumab Injection;Drug: Bendamustine;Drug: Pomalidomide;Drug: Ixazomib;Drug: Venetoclax MTD with Dexamethasone | Rajshekhar Chakraborty, MD | Genentech, Inc. | Recruiting | 18 Years | N/A | All | 53 | Phase 1/Phase 2 | United States |
49. Systemic lupus erythematosus
Clinical trials : 993 / Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04810754 (ClinicalTrials.gov) | June 30, 2021 | 11/3/2021 | An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus Erythematosus | A Monocenter, Open Label Study to Evaluate the Safety and Efficacy of Daratumumab in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | Drug: Daratumumab Injection | Charite University, Berlin, Germany | Janssen-Cilag G.m.b.H;Labor Berlin-Charité Vivantes G.m.b.H;Deutsches Rheuma-Forschungszentrum Berlin (DRFZ);Charité Clinical Trial Office (CTO) | Not yet recruiting | 18 Years | 60 Years | All | 10 | Phase 2 | NULL |
63. Idiopathic thrombocytopenic purpura
Clinical trials : 391 / Drugs : 235 - (DrugBank : 50) / Drug target genes : 49 - Drug target pathways : 139
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05562882 (ClinicalTrials.gov) | October 15, 2022 | 28/9/2022 | A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia | A Investigator-initiated Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Relapsed/Refractory Primary Immune Thrombocytopenia | Immune Thrombocytopenia | Drug: Daratumumab Injection | Institute of Hematology & Blood Diseases Hospital | NULL | Not yet recruiting | 18 Years | N/A | All | 20 | Early Phase 1 | NULL |